| Literature DB >> 29423263 |
Li Hou1, Chunguang Fan1, Chenghu Liu1, Qiujin Qu1, Chunren Wang2, Yanping Shi1.
Abstract
Systemic toxicity caused by repeated exposure to both polar and nonpolar leachables of di(2-ethylhexyl)-1,2-cyclohexane plasticized polyvinyl chloride (PVC) was evaluated with dual routes of parenteral administration method on rats in the study. Experimental group and control group were designed by researchers. Tail intravenous injection with 0.9% sodium chloride injection extracts and intraperitoneal injection with corn oil extracts were conducted to the experimental rats while tail intravenous injection with 0.9% sodium chloride Injection and intraperitoneal injection with corn oil were conducted to the control rats. After 14 days, blood specimens were collected for clinical pathology (hematology and clinical chemistry) analysis. Selected organs were weighed and a histopathological examination was conducted. As a result, compared with the control animals, there were no toxicity-related changes on the parameters above. The results show that the rats do not show obvious systemic toxicity reaction caused by repeated exposure with dual routes of parenteral administration method on rats after administration with both polar and nonpolar exacts of di(2-ethylhexyl)-1,2-cyclohexane plasticized PVC simultaneously up for 14 days.Entities:
Keywords: dual routes of parenteral administration method; plasticized PVC; repeated exposure systemic toxicity test
Year: 2018 PMID: 29423263 PMCID: PMC5798126 DOI: 10.1093/rb/rbx020
Source DB: PubMed Journal: Regen Biomater ISSN: 2056-3426
Extraction preparation methods
| Group | Extraction ratio | Extraction temperature | Extraction time | Vehicles/controls |
|---|---|---|---|---|
| Test | 0.2 g/ml | 37±1 °C | 72±2 h | 0.9% sodium chloride injection and corn oil |
| Control | N/A | 37±1 °C | 72±2 h | 0.9% sodium chloride injection and corn oil |
Administration methods
| Routes | Dosage volume (ml/kg·BW) | Dose frequency | Rate |
|---|---|---|---|
| Intravenous | 10 | Daily for 14 days | ≤2 ml/min |
| Intraperitoneal | 5 | 1, 4, 7, 10, 13 | Slow bonus |
Parameters and abbreviations of clinical pathology analyses
| Hematology | Clinical chemistry analyses |
|---|---|
| White blood cell (WBC) | Alanine amino transferase (ALT) |
| Red blood cell (RBC) | Aspartate amino transferase (AST) |
| Hemoglobin (Hgb) | Alkaline phosphatase (ALP) |
| Hematocrit (Hct) | γ-glutamyl transpeptidase (γ-GT) |
| Platelet (PLT) | Total bilirubin (TBIL) |
| Neutrophils proportion (NEUT%) | Total protein (TP) |
| Lymphocytes proportion (LYMPH%) | Albumin (ALB) |
| Monocytes proportion (MONO%) | Glucose (GLU) |
| Eosinophils proportion (EO%) | Creatinine (CREA) |
| Basophils proportion (BASO%) | Urea (UREA) |
| Prothrombin time (PT) | Cholesterol (CHOL) |
| Activated partial thromboplastin time (APTT) | Triglyceride (TG) |
| Calcium ion (Ca2+) | |
| Inorganic Phosphorus (IP) | |
| Sodion (Na+) | |
| Kalium ion (K+) | |
| Chloridion (Cl-) |
Figure 1Weight trend line chart
Summary of body weight data (g, mean±SD)
| Week | Control (F) | Test (F) | Control (M) | Test (M) |
|---|---|---|---|---|
| Week 0 | 193.7±9.7 | 194.7±7.9 | 238.0±7.3 | 236.2±9.4 |
| Week 1 | 210.8±8.7 | 210.1±10.3 | 268.9±8.1 | 267.7±13.2 |
| Week 2 | 237.7±13.4 | 235.2±11.5 | 334.5±14.6 | 336.2±20.4 |
F: Female, M: Male.
Summary of hematology data (mean±SD)
| Parameters | Control (F) | Test (F) | Control (M) | Test (M) |
|---|---|---|---|---|
| WBC (109/l) | 3.73±1.25 | 4.30±0.95 | 4.44±1.61 | 4.35±1.23 |
| RBC (1012/l) | 6.57±0.34 | 6.45±0.21 | 6.93±0.30 | 6.68±0.37 |
| Hgb (g/l) | 127.20±4.78 | 125.50±3.41 | 134.70±4.32 | 129.30±7.21 |
| Hct (%) | 36.98±1.45 | 36.36±0.90 | 39.42±1.12 | 38.05±1.93 |
| PLT (109/l) | 1074.70±83.33 | 1040.20±51.54 | 1140.50±108.79 | 1163.20±129.66 |
| NEUT (%) | 14.11±6.77 | 7.91±4.37 | 7.83±3.20 | 6.64±2.06 |
| LYMPH (%) | 75.88±7.11 | 81.95±4.45 | 82.10±3.36 | 82.69±2.68 |
| MONO (%) | 8.75±1.94 | 9.11±2.38 | 9.46±1.22 | 10.19±2.20 |
| EO (%) | 1.26±0.69 | 1.03±0.63 | 0.59±0.12 | 0.48±0.28 |
| BASO (%) | 0.00±0.00 | 0.00±0.00 | 0.02±0.06 | 0.00±0.00 |
| PT (s) | 8.16±0.31 | 8.11±0.27 | 8.94±0.61 | 9.06±0.30 |
| APTT (s) | 21.39±4.63 | 20.57±5.00 | 21.03±3.91 | 21.50±4.40 |
P<0.05.
Summary of clinical chemistry data (mean±SD)
| Parameters | Control (F) | Test (F) | Control (M) | Test (M) |
|---|---|---|---|---|
| ALT (U/l) | 51.67±49.14 | 35.93±12.15 | 44.68±11.83 | 44.69±7.93 |
| AST (U/l) | 150.66±89.39 | 132.74±30.99 | 137.68±24.19 | 142.30±25.18 |
| ALP (U/l) | 103.88±21.16 | 90.98±19.58 | 232.80±37.72 | 233.83±36.30 |
| γ-GT (U/l) | 0.53±0.42 | 0.49±0.74 | 0.72±0.31 | 0.97±0.27 |
| TBIL (µmol/l) | 0.48±0.23 | 0.48±0.21 | 0.39±0.15 | 0.32±0.19 |
| TP (g/l) | 57.00±3.58 | 57.12±5.20 | 51.46±2.18 | 52.09±1.91 |
| ALB (g/l) | 34.61±2.21 | 34.53±3.33 | 29.45±1.22 | 29.17±1.18 |
| GLU (mmol/l) | 6.59±0.34 | 7.08±0.50 | 6.43±0.61 | 6.58±0.47 |
| CREA (µmol/l) | 25.68±3.09 | 27.71±2.12 | 22.80±2.24 | 22.83±1.16 |
| UREA (mmol/l) | 5.29±0.67 | 5.98±0.95 | 4.24±0.45 | 4.37±0.42 |
| CHOL (mmol/l) | 1.32±0.22 | 1.49±0.38 | 1.50±0.30 | 1.53±0.25 |
| TG (mmol/l) | 0.26±0.05 | 0.31±0.09 | 0.36±0.15 | 0.29±0.10 |
| Ca2+ (mmol/l) | 2.26±0.06 | 2.24±0.08 | 2.19±0.05 | 2.18±0.05 |
| IP (mmol/l) | 2.46±0.20 | 2.36±0.07 | 2.77±0.13 | 2.80±0.17 |
| Na+ (mmol/l) | 139.58±1.75 | 140.13±1.05 | 142.20±0.83 | 141.68±0.71 |
| K+ (mmol/l) | 4.09±0.24 | 4.04±0.22 | 4.33±0.18 | 4.28±0.22 |
| Cl- (mmol/l) | 104.02±1.46 | 104.18±1.00 | 104.71±1.34 | 103.61±1.40 |
P<0.05.
Summary of organ/body weight ratios data (mean±SD)
| Organs | Control (F) | Test (F) | Control (M) | Test (M) |
|---|---|---|---|---|
| Brain | 0.750±0.065 | 0.761±0.035 | 0.585±0.042 | 0.573±0.036 |
| Thymus | 0.168±0.017 | 0.182±0.032 | 0.182±0.035 | 0.161±0.028 |
| Heart | 0.308±0.021 | 0.322±0.026 | 0.334±0.036 | 0.306±0.025 |
| Liver | 2.834±0.178 | 2.873±0.239 | 2.713±0.150 | 2.833±0.106 |
| Spleen | 0.220±0.028 | 0.269±0.037 | 0.202±0.031 | 0.222±0.034 |
| Adrenal | 0.027±0.002 | 0.027±0.004 | 0.015±0.003 | 0.013±0.002 |
| Kidneys | 0.772±0.058 | 0.757±0.035 | 0.734±0.037 | 0.766±0.033 |
| Ovaries/testes | 0.053±0.009 | 0.053±0.011 | 0.908±0.075 | 0.873±0.072 |
| Uterus/epididymises | 0.237±0.091 | 0.250±0.078 | 0.228±0.046 | 0.193±0.013 |
P<0.05.
Figure 2The oil retained in the abdominal cavity at necropsy after 14 days of administration, as shown by the arrow
Figure 3The organ histopathology pictures of the treatment group. (A) Liver (HE, ×200), (B) spleen (HE, ×400), (C) kidney (HE, ×400), (D) thymus (HE, ×400), (E) testicle (HE, ×200), (F) heart (HE, ×400)